A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1

NCT ID: NCT01448200

Last Updated: 2012-11-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-31
• Study Completion Date: 2012-11-30

Brief Summary

PPI-668 is an antiviral agent (a hepatitis C NS5A inhibitor) that is being developed as a potential treatment for hepatitis C virus infection. This study is being done to assess the safety and tolerance of PPI-668 when given to healthy volunteers for up to 5 days (Part I of the study) and to hepatitis C patients for up to 3 days (Part II). In addition, the study will assess how much PPI-668 is absorbed into the bloodstream. In Part II, the effect of PPI-668 on the amount of hepatitis C virus in patients' bloodstream (serum HCV RNA levels) also will be assessed.

Conditions

Hepatitis C, Chronic

Keywords

hepatitis C; NS5A inhibitor; Phase 1; genotype-1; genotype-2; genotype-3

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Part I: single dose escalation in healthy volunteers

There will be three sequential single dose cohorts:

Cohort A: PPI-668 dose D1 or placebo

Cohort B: PPI-668 dose D2 or placebo

Cohort C: PPI-668 dose D3 or placebo

Group Type: EXPERIMENTAL

PPI-668

Intervention Type: DRUG

capsules

Placebo

Intervention Type: DRUG

capsules

Part I: multiple dose administration to healthy volunteers

Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:

Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days

Group Type: EXPERIMENTAL

PPI-668

Intervention Type: DRUG

capsules

Placebo

Intervention Type: DRUG

capsules

Part II: multiple dose escalation in HCV subjects

Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:

Cohort E (genotype-1): PPI-668 dose E1 or placebo

Cohort F (genotype-1): PPI-668 dose E2 or placebo

Cohort G (genotype-1): PPI-668 dose E3 or placebo

Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined

Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo

Group Type: EXPERIMENTAL

PPI-668

Intervention Type: DRUG

capsules

Placebo

Intervention Type: DRUG

capsules

Interventions

PPI-668

capsules

Intervention Type: DRUG

Placebo

capsules

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, between 18 and 65 years of age. Female patients must be surgically sterile or two years post-menopausal.

2. Body Mass Index (BMI) 18 - 35 kg/m2

3. In good health, in the judgment of the Principal Investigator

4. Able and willing to comply with all protocol requirements and to sign an informed consent.

Exclusion Criteria

1. Seropositive for HIV antibody, or HBV surface antigen (HBsAg) at Screen. Volunteer subjects for Part I must also be negative for HCV antibody.

2. Any medical condition that may interfere with the absorption, distribution or elimination of study drug (PPI-668), or with the clinical and laboratory assessments in this study.

3. Poorly controlled or unstable hypertension; or sustained systolic BP > 150 or diastolic BP > 95 at Screen.

4. History of Diabetes Mellitus treated with insulin or hypoglycemic agents

5. History of alcohol abuse or illicit drug use which, in the investigator's judgment, could interfere with a patient's compliance, with the protocol requirements or with the safety or efficacy assessments of the study

6. History of malignancy unless the malignancy has been in complete remission and without additional medical or surgical interventions during the preceding three years

7. No clinically significant laboratory abnormalities at Screen for healthy volunteers in Part I. For Screen laboratory parameters for HCV patients in Part II, refer to the 'Additional Criteria for HCV Patients' below.

Additional Key Entry Criteria for HCV patients (Part II):

1. Clinical diagnosis of chronic hepatitis C, documented by:

1. Clinical findings compatible with chronic hepatitis C, and absence of other known liver disease

2. Seropositive for HCV antibody or HCV RNA at least once previously, and at Screen

3. Serum HCV RNA > 5 log10 IU/mL at Screen, by the PCR assay at the central study laboratory

4. HCV genotype-1 (1a or 1b, or non-subtypable genotype-1), or HCV genotype-2a or genotype-3a

2. ALT must be <5 x ULN at screen

3. No previous treatment with interferon, pegIFN, or ribavirin for genotype-1 patients

4. No history of signs or symptoms of decompensated liver disease

5. Any of the following laboratory values at Screening will be exclusionary for study participation:

• Hgb <11 g/dL in women or 12 g/dL in men.
• White blood cell count < 4,000/mm3.
• Absolute neutrophil count (ANC) < 1800 per mm3.
• Platelet count < 100,000 per mm3.
• Serum creatinine >ULN at the central study laboratory.
• Serum albumin < 3.4 g/dL.
• Total bilirubin > 2.0 mg/dL
• Clinically significant abnormality in the electrocardiograms (ECGs) at Screen

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Presidio Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nathaniel Brown, M.D.

Role: STUDY_DIRECTOR

Presidio Pharmaceuticals, Inc.

Locations

Investigational site

Costa Mesa, California, United States

Investigational site

Sacramento, California, United States

Investigational site

San Francisco, California, United States

Investigational Site

San Antonio, Texas, United States

Investigational site

Canberra, , Australia

Investigational site

Auckland, , New Zealand

Investigational site

Christchurch, , New Zealand

Countries

United States; Australia; New Zealand

Other Identifiers

PPI-668-101

Identifier Type: -

Identifier Source: org_study_id